Ashland (ASH) reported $463 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 14.9%. EPS of $1.04 for the same period compares to $1.49 a year ago.
The reported revenue represents a surprise of -1.15% over the Zacks Consensus Estimate of $468.37 million. With the consensus EPS estimate being $1.15, the EPS surprise was -9.57%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Intermediates: $33 million versus the two-analyst average estimate of $34.81 million. The reported number represents a year-over-year change of -8.3%.
- Revenue- Specialty Additives: $131 million versus $123.73 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -12.7% change.
- Revenue- Personal Care: $147 million versus the two-analyst average estimate of $146.57 million. The reported number represents a year-over-year change of -16%.
- Revenue- Life Sciences: $162 million versus the two-analyst average estimate of $169.65 million. The reported number represents a year-over-year change of -16.9%.
- Adjusted EBITDA- Life Science: $54 million compared to the $55.16 million average estimate based on two analysts.
- Adjusted EBITDA- Intermediates: $7 million compared to the $3.48 million average estimate based on two analysts.
- Adjusted EBITDA- Specialty Additives: $26 million versus the two-analyst average estimate of $26.25 million.
- Adjusted EBITDA- Personal Care: $41 million versus $43.05 million estimated by two analysts on average.
View all Key Company Metrics for Ashland here>>>
Shares of Ashland have returned +1.3% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ashland Inc. (ASH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
